Just 11% of Ukrainians who had been previously against vaccination changed their opinion after the disease

Among 70% of those who have had COVID-19 the attitude towards vaccination has not changed: 44% continue to consider it to be necessary and 26% are still against it. Only 11% of respondents who were previously against vaccination changed their opinions to the opposite after getting sick according to Gradus Research study*, commissioned by pharmaceutical company “Darnitsa”

The most frequently stated reasons for refusing to vaccinate against COVID-19 are the opinion that the vaccine has not sufficiently been tested yet (67%) and fear of side-effects (64%).

COVID-19 vaccination is equally supported by those who have had COVID-19 and those who have not – 63% and 63%.

The vast majority (88%) of those vaccinated with at least single dose against COVID-19 have a certificate of vaccination against COVID-19. More than half (63%) of the certificate holders have it in electronic format, in the “Dia” app.

The support for restrictions on using transport and visiting public institutions does not significantly depend on whether the respondents were sick with COVID-19 or not. 44% of those who had been ill and 47% of those who had not support restrictions on using public transport. 43% of those who had been sick and 50% of those who had not supported restrictions on visiting public institutions.

It is worth reminding that pharmaceutical company “Darnitsa” has created a platform postcovid.darnitsa.ua** about post-COVID-19 syndrome. The uniqueness of the resource lies in the fact that “Darnitsa” collects, analyses and systematizes international and domestic practice and research and makes it accessible to a wide audience. Every word and every piece of advice is supported by evidence-based medicine, and information on symptoms is regularly updated.

Reference

PJSC Pharmaceutical Company “Darnitsa” was founded in 1930 and is celebrating its 91st anniversary this year. Since 1998, “Darnitsa” has been Ukraine’s leader in the production of medicines in volume terms. The strategic areas of portfolio development are cardiology, neurology and pain management. During 2015-2020, “Darnitsa” has launched 50 pharmaceutical brands on the market.

*Gradus Research study commissioned by pharmaceutical company “Darnitsa”, 1527 interviews, men and women aged 18-60, living in Kharkiv, Kyiv, Lviv, Odesa, Zaporizhzhia and Dnipro, November 2-4, 2021.

**The information on this website is purely for informational purposes and cannot be used for self-diagnosis or self-treatment.